The stock of Fluidigm Corporation (NASDAQ:FLDM) is a huge mover today! About 126,834 shares traded hands or 4.26% up from the average. Fluidigm Corporation (NASDAQ:FLDM) has risen 5.62% since March 8, 2016 and is uptrending. It has underperformed by 3.70% the S&P500.
The move comes after 5 months negative chart setup for the $212.80M company. It was reported on Oct, 11 by Barchart.com. We have $6.49 PT which if reached, will make NASDAQ:FLDM worth $25.54M less.
Analysts await Fluidigm Corporation (NASDAQ:FLDM) to report earnings on November, 3. They expect $-0.54 EPS, down 80.00% or $0.24 from last year’s $-0.3 per share. After $-0.47 actual EPS reported by Fluidigm Corporation for the previous quarter, Wall Street now forecasts 14.89% negative EPS growth.
Fluidigm Corporation (NASDAQ:FLDM) Ratings Coverage
Out of 5 analysts covering Fluidigm (NASDAQ:FLDM), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Fluidigm has been the topic of 17 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The rating was upgraded by Cantor Fitzgerald on Friday, October 30 to “Buy”. The firm has “Sell” rating given on Friday, August 21 by Zacks. Deutsche Bank initiated it with “Buy” rating and $18 target price in Thursday, January 7 report. Maxim Group maintained the stock with “Hold” rating in Thursday, August 27 report. The firm earned “Buy” rating on Friday, August 5 by Cantor Fitzgerald. On Friday, October 30 the stock rating was maintained by Mizuho with “Neutral”. Mizuho maintained the stock with “Hold” rating in Sunday, August 9 report. The firm has “Neutral” rating by Piper Jaffray given on Friday, August 7. The rating was initiated by Cantor Fitzgerald on Wednesday, August 26 with “Hold”. Mizuho maintained the stock with “Neutral” rating in Friday, August 7 report.
According to Zacks Investment Research, “Fluidigm Corporation operates as a biotech tools company that creates microfluidic-based chips and instrumentation for biological research. Products offered by the Company include BioMark HD System- a real time PCR; EP1 system for SNP genotyping; Access Array System-an Integrated Fluidic Circuit (IFC); TOPAZ system for protein crystallography; Dynamic Array integrated fluidic circuits (IFCs); and Access Array Assay Design Services. The Company’s products find its application in Gene Expression, Single-Cell Gene Expression, SNP Genotyping, Targeted Resequencing, Sample Quantitation, Copy Number Variation and Protein Crystallization. Fluidigm Corporation is based in San Francisco, California.”
Insitutional Activity: The institutional sentiment decreased to 0.82 in Q2 2016. Its down 0.14, from 0.96 in 2016Q1. The ratio worsened, as 14 funds sold all Fluidigm Corporation shares owned while 31 reduced positions. 8 funds bought stakes while 29 increased positions. They now own 25.56 million shares or 9.86% less from 28.35 million shares in 2016Q1.
Stoneridge Inv Prtn Lc, a Pennsylvania-based fund reported 24,396 shares. Blackrock Grp Incorporated, a United Kingdom-based fund reported 11,747 shares. Blackrock Institutional Tru Na last reported 797,605 shares in the company. Moreover, Millennium Management Llc has 0.01% invested in Fluidigm Corporation (NASDAQ:FLDM) for 256,409 shares. Sei Invests, a Pennsylvania-based fund reported 3,334 shares. Panagora Asset Inc holds 1,673 shares or 0% of its portfolio. Blackrock Inc accumulated 0% or 2,447 shares. Teacher Retirement Sys Of Texas owns 3,602 shares or 0% of their US portfolio. Polar Cap Limited Liability Partnership accumulated 0.01% or 54,132 shares. Endurant Cap Mngmt L P holds 0.77% of its portfolio in Fluidigm Corporation (NASDAQ:FLDM) for 256,490 shares. Commercial Bank Of New York Mellon last reported 185,974 shares in the company. Manufacturers Life Insur Communication The holds 22,238 shares or 0% of its portfolio. Fic, a New York-based fund reported 188,700 shares. Principal Financial Gru accumulated 77,393 shares or 0% of the stock. Wellington Gp Llp holds 0% of its portfolio in Fluidigm Corporation (NASDAQ:FLDM) for 652,516 shares.
More notable recent Fluidigm Corporation (NASDAQ:FLDM) news were published by: Quotes.Wsj.com which released: “Fluidigm Corp. FLDM (US: Nasdaq)” on February 11, 2011, also Fool.com with their article: “Why Fluidigm Corporation is Soaring Higher” published on October 30, 2015, Fool.com published: “Why Shares in Fluidigm Corporation Are Bursting” on May 08, 2015. More interesting news about Fluidigm Corporation (NASDAQ:FLDM) were released by: Globenewswire.com and their article: “Fluidigm Appoints New President and Chief Operating Officer” published on August 04, 2016 as well as Businesswire.com‘s news article titled: “Fluidigm Introduces Advanced Mass Cytometry System Along With Sample Barcoding …” with publication date: June 25, 2015.
FLDM Company Profile
Fluidigm Corporation, incorporated on March 29, 2007, creates, makes and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Firm sells instruments and consumables, including integrated fluidic circuits, assays and reagents, to academic institutions, clinical laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology (Ag-Bio) companies. The Firm operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. The Firm offers various types of products, which include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.